title: Management of locally advanced adenocarcinoma of the pancreas.
abstract: Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals. For locally advanced disease, the combination of 5-FU and radiation appears to offer the best chance for delaying disease progression. The introduction of gemcitabine into chemoradiotherapy regimens may provide additional improvements in the management of patients. Preoperative therapy has proved feasible but has not shown improvement in overall survival.
authors.affiliation: Gastrointestinal Cancer Center, Massachusetts General Hospital, Harvard Medical School, Cox 640, 100 Blossom Street, Boston, MA 02114, USA. dpryan@partners.org
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008937:Mitomycins / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011867:Radioisotope Teletherapy; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013311:Streptozocin / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D008937:Mitomycins; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D013311:Streptozocin; D004317:Doxorubicin; D017239:Paclitaxel; D005472:Fluorouracil; D000093542:Gemcitabine